ProCE Banner Activity

Efficacy and Safety of Treatment Withdrawal and Retreatment With Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis

Slideset Download
Conference Coverage
Upadacitinib retreatment was safe and effective in patients who had treatment withdrawn.

Released: July 27, 2020

Expiration: July 26, 2021

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

This educational activity is supported by educational grants from

AbbVie Inc.

Pfizer, Inc.